BioSpace News Archive

- Biohaven and Genpharm’s agreement will bring NURTEC™ ODT, the first oral, quick-dissolve, calcitonin gene related peptide (CGRP) antagonist to patients in the Middle East and the Gulf Region - Registration in the Middle East is based upon Biohaven’s NURTEC™ ODT approval in the US [27-April-2020] NEW HAVEN, Conn. , April 27, 2020 /PRNewswire/ -- Biohaven Ph

Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its first quarter 2020 financial results before markets open on Monday, May 11, 2020.

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is delighted to announce that Mr. Amir Boloor has joined its Board of Directors. Brian Pedlar, Covalon’s CEO, said, “I am delighted that Amir Boloor has agreed to join Covalon’s Board. Amir has been a significant long-time Covalon shareholder and he has much to offer us in terms of advice

Novocure ) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune for the treatment of recurrent GBM will be presented as a virtual poster at the American Association for Cancer Research (AACR) 2020 Virtu

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the crucial pyrogenicity testing that is required by the U.S. Food and Drug Administration (FDA) of the encapsulation material used to manufacture PharmaCyte’s Cell

Stryker announced that Stryker B.V., an indirect, wholly owned subsidiary of Stryker, has extended the offering period of its previously announced cash tender offer for all outstanding ordinary shares of Wright Medical Group N.V..

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the nomination of biotech industry veteran Terri Shoemaker to the Company’s Board of Directors. Ms. Shoemaker brings more than 30 years of extensive commercial and leadership experience to Onconova. Ms. Shoemaker will j

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on ongoing nVNS COVID-19 initiatives.

In response to the global COVID-19 pandemic, Erba Mannheim announced the development and imminent launch of its ErbaLisa® COVID-19 ELISA kits for detection of IgG and IgM antibodies to SARS-CoV-2.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the European Medicines Agency (EMA) has completed its